Heart shield for chemo: carvedilol may protect breast cancer Patients' hearts
NCT ID NCT04023110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether the heart medication carvedilol could safely protect breast cancer patients from heart damage caused by chemotherapy drugs like doxorubicin and trastuzumab. 68 women with early-stage breast cancer were assigned to either receive carvedilol or standard care based on their personal heart risk. The main goals were to see if the approach was safe, tolerable, and practical, not to prove it prevents heart failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Liver clues: a new way to stage heart amyloidosis?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?